EG24678A - Combination therapy - Google Patents

Combination therapy

Info

Publication number
EG24678A
EG24678A EG102598A EG102598A EG24678A EG 24678 A EG24678 A EG 24678A EG 102598 A EG102598 A EG 102598A EG 102598 A EG102598 A EG 102598A EG 24678 A EG24678 A EG 24678A
Authority
EG
Egypt
Prior art keywords
combination therapy
therapy
combination
Prior art date
Application number
EG102598A
Other languages
English (en)
Inventor
Robert A Scott
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of EG24678A publication Critical patent/EG24678A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
EG102598A 1997-08-29 1998-08-27 Combination therapy EG24678A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5727697P 1997-08-29 1997-08-29

Publications (1)

Publication Number Publication Date
EG24678A true EG24678A (en) 2010-04-27

Family

ID=22009602

Family Applications (1)

Application Number Title Priority Date Filing Date
EG102598A EG24678A (en) 1997-08-29 1998-08-27 Combination therapy

Country Status (41)

Country Link
US (2) US20020099046A1 (id)
EP (1) EP1009400B1 (id)
JP (2) JP2001514223A (id)
KR (3) KR20040106591A (id)
CN (3) CN1268053A (id)
AP (1) AP1191A (id)
AR (1) AR016399A1 (id)
AT (1) ATE285767T1 (id)
AU (1) AU740424B2 (id)
BG (1) BG64724B1 (id)
BR (1) BR9811556A (id)
CA (1) CA2296723A1 (id)
CO (1) CO4970724A1 (id)
DE (1) DE69828413T2 (id)
DZ (1) DZ2595A1 (id)
EA (1) EA200000012A1 (id)
EG (1) EG24678A (id)
ES (1) ES2234134T3 (id)
GT (1) GT199800126A (id)
HR (1) HRP980474A2 (id)
HU (1) HUP0004318A3 (id)
ID (1) ID24118A (id)
IL (2) IL133962A0 (id)
IS (1) IS5341A (id)
MA (1) MA26536A1 (id)
MY (1) MY121008A (id)
NO (1) NO323987B1 (id)
NZ (2) NZ530630A (id)
OA (1) OA11291A (id)
PA (1) PA8457901A1 (id)
PE (1) PE107099A1 (id)
PL (1) PL339091A1 (id)
PT (1) PT1009400E (id)
SA (1) SA98190603B1 (id)
SK (1) SK1432000A3 (id)
TN (1) TNSN98155A1 (id)
TR (1) TR200000563T2 (id)
UY (1) UY25155A1 (id)
WO (1) WO1999011260A1 (id)
YU (1) YU2000A (id)
ZA (1) ZA987839B (id)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
AU1591699A (en) * 1998-03-17 1999-10-11 Warner-Lambert Company Statin-matrix metalloproteinase inhibitor combinations
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
AU2007200367B2 (en) * 1999-02-06 2010-04-08 Astrazeneca Ab Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
ATE309807T1 (de) 1999-09-24 2005-12-15 Vasogen Ireland Ltd Zusammensetzung zur behandlung von atherosklerose,welche ein statin und ex-vivo behandeltes blut enthält
FR2803525B1 (fr) * 2000-01-06 2002-05-03 Sod Conseils Rech Applic Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
SE0002354D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New formulation
AR032758A1 (es) 2000-07-19 2003-11-26 Novartis Ag Sales valsartan, un proceso para su fabricacion, composiciones farmaceuticas y el uso de dichas sales para la preparacion de medicamentos
WO2002017913A1 (fr) * 2000-08-30 2002-03-07 Sankyo Company, Limited Compositions medicinales utilisees dans la prevention ou le traitement de l'insuffisance cardiaque
US7018649B2 (en) * 2000-10-23 2006-03-28 Euro-Celtique, S.A. Felodipine transdermal device and methods
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
KR20040023660A (ko) * 2001-07-19 2004-03-18 파마시아 코포레이션 알도스테론 수용체 길항제 및 ｈｍｇ ｃｏａ 환원효소억제제의 병용물
US20030114497A1 (en) * 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
US6852737B2 (en) * 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
ATE395936T1 (de) * 2002-06-20 2008-06-15 Univ Alberta Dichloracetat in kombination mit kardioprotektiven oder hämodynamischen medikamenten
CN101898995B (zh) * 2002-06-27 2013-05-01 史密斯克莱·比奇曼（科克）有限公司 卡维地洛磷酸盐和/或其溶剂合物相应的组合物和/或治疗方法
JP2005533822A (ja) * 2002-06-27 2005-11-10 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド 臭化水素酸カルベジロール
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
GB0221579D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Combinations of atorvastatin and, adrenergic receptor antagonists
JP2006504800A (ja) * 2002-10-16 2006-02-09 レコーダチ アイルランド リミテッド リシノプリル／レルカニジピンの組み合わせ治療
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
EP1686967A4 (en) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES
EP1691789B1 (en) * 2003-11-25 2017-12-20 SmithKline Beecham (Cork) Limited Carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
US7750036B2 (en) * 2003-11-25 2010-07-06 Sb Pharmco Puerto Rico Inc. Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
KR20050092519A (ko) * 2004-03-16 2005-09-22 화이자 인코포레이티드 아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합
EP1734958A1 (en) * 2004-04-06 2006-12-27 Merck & Co., Inc. Methods for the treatment of hypertension
PL1750862T3 (pl) 2004-06-04 2011-06-30 Teva Pharma Kompozycja farmaceutyczna zawierająca irbesartan
EP1781265B1 (en) 2004-08-25 2010-04-07 Essentialis, Inc. Pharmaceutical formulations of potassium atp channel openers and uses thereof
ES2369787T3 (es) * 2005-02-17 2011-12-07 Chiesi Farmaceutici S.P.A. Combinaciones terapéuticas de manidipina y simvastatina.
PT2000137E (pt) * 2006-03-29 2016-02-17 Kowa Co Agente redutor de triglicerídeos e agente melhorador de hiperinsulinismo
CA2664893C (en) * 2006-10-30 2015-01-27 Hanall Pharmaceutical Company, Ltd. Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors
WO2009134057A2 (ko) 2008-04-29 2009-11-05 한올제약주식회사 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
CZ2008740A3 (cs) * 2008-11-24 2010-01-06 Zentiva, A.S. Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem
CN102292085B (zh) * 2009-01-23 2017-01-18 韩美科学株式会社 包含氨氯地平和氯沙坦的固体药物组合物及其制备方法
SI23149A (sl) * 2009-09-21 2011-03-31 Silverstone Pharma Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni
RU2481124C1 (ru) * 2011-10-27 2013-05-10 Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" Фармацевтическая комбинация из аторвастатина и ницерголина для профилактики или лечения нарушений мозгового кровообращения
CN102671198A (zh) * 2011-12-17 2012-09-19 东莞达信生物技术有限公司 一种降压降脂复方药及其制备方法
KR20140028971A (ko) * 2012-08-31 2014-03-10 한미약품 주식회사 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
BR112015022103A2 (pt) * 2013-03-12 2017-07-18 Lg Life Sciences Ltd composição farmacêutica, método para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para prevenir ou tratar uma doença
CN104173420A (zh) * 2013-05-20 2014-12-03 广州诺氏刘生物科技有限公司 一种治疗急性肾衰竭的药物
AU2015335841B2 (en) 2014-10-23 2020-06-25 Arena Pharmaceuticals, Inc. Method of treating conditions related to the PGI2 receptor
CN108156807A (zh) * 2015-06-30 2018-06-12 韩美药品株式会社 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂
FR3040303B1 (fr) * 2015-08-27 2019-04-05 Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca
CN105232555A (zh) * 2015-11-19 2016-01-13 哈尔滨圣吉药业股份有限公司 一种替米沙坦/瑞舒伐他汀复方制剂及其制备方法
BR112018075067A2 (pt) * 2016-06-02 2019-04-30 Ana Pharmaceuticals, Inc. métodos para o tratamento de hipercalciúria e nefrolitíase, composição terapêutica, composição nutricional, kit
EP4374915A2 (en) 2017-01-25 2024-05-29 The George Institute For Global Health Compositions for the treatment of hypertension
WO2018160882A1 (en) 2017-03-01 2018-09-07 Arena Pharmaceuticals, Inc. Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
KR20210038931A (ko) * 2018-07-26 2021-04-08 더 조지 인스티튜트 포 글로벌 헬스 고혈압 치료용 조성물
CN112826937B (zh) * 2021-03-25 2022-03-22 山东大学齐鲁医院 艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
TW474809B (en) * 1995-07-03 2002-02-01 Sankyo Co A pharmaceutical composition for arteriosclerosis or xanthoma consisting of HMG-CoA reductase inhibitors and insulin sensitizers
SK284142B6 (sk) * 1995-11-02 2004-10-05 Warner-Lambert Company Farmaceutická kompozícia na reguláciu koncentrácie lipidov, stabilizáciu aterosklerotických lézií a na prevenciu pretrhnutia aterosklerotického plaku

Also Published As

Publication number Publication date
KR20040106591A (ko) 2004-12-17
EP1009400A1 (en) 2000-06-21
CA2296723A1 (en) 1999-03-11
JP2005041875A (ja) 2005-02-17
BR9811556A (pt) 2000-08-22
BG64724B1 (bg) 2006-01-31
AP9801332A0 (en) 1998-09-30
AP1191A (en) 2003-07-19
PL339091A1 (en) 2000-12-04
HUP0004318A3 (en) 2002-10-28
US20030199492A1 (en) 2003-10-23
KR20030015394A (ko) 2003-02-20
HRP980474A2 (en) 1999-06-30
NZ530630A (en) 2005-05-27
NO20000996D0 (no) 2000-02-28
WO1999011260A1 (en) 1999-03-11
ID24118A (id) 2000-07-06
MY121008A (en) 2005-12-30
ES2234134T3 (es) 2005-06-16
YU2000A (sh) 2002-12-10
DE69828413T2 (de) 2005-12-08
MA26536A1 (fr) 2004-12-20
CN1473566A (zh) 2004-02-11
PE107099A1 (es) 1999-11-06
KR20010022477A (ko) 2001-03-15
NZ502280A (en) 2002-11-26
NO20000996L (no) 2000-04-27
HUP0004318A2 (hu) 2001-05-28
PA8457901A1 (es) 2000-05-24
SA98190603B1 (ar) 2006-07-04
TNSN98155A1 (fr) 2005-03-15
EP1009400B1 (en) 2004-12-29
IL133962A (en) 2006-07-05
CN1268053A (zh) 2000-09-27
PT1009400E (pt) 2005-02-28
IS5341A (is) 2000-01-14
ATE285767T1 (de) 2005-01-15
BG104075A (en) 2000-09-29
SK1432000A3 (en) 2000-12-11
TR200000563T2 (tr) 2000-07-21
UY25155A1 (es) 2000-12-29
US20020099046A1 (en) 2002-07-25
IL133962A0 (en) 2001-04-30
DZ2595A1 (fr) 2003-02-22
GT199800126A (es) 2000-01-29
DE69828413D1 (de) 2005-02-03
AU8458998A (en) 1999-03-22
EA200000012A1 (ru) 2000-08-28
JP2001514223A (ja) 2001-09-11
ZA987839B (en) 2000-02-28
OA11291A (en) 2003-08-25
CO4970724A1 (es) 2000-11-07
CN1473567A (zh) 2004-02-11
NO323987B1 (no) 2007-07-30
AU740424B2 (en) 2001-11-01
AR016399A1 (es) 2001-07-04

Similar Documents

Publication Publication Date Title
EG24678A (en) Combination therapy
GB9708484D0 (en) Therapeutic agents
GB9708945D0 (en) Therapeutic agents
GB9704948D0 (en) Therapeutic agents
ZA987843B (en) Combination therapy.
IL127306A0 (en) Combination therapy
ZA982368B (en) New therapeutic combinations
GB9702524D0 (en) Therapeutic agents
GB9711753D0 (en) Therapeutic agents
GB9713707D0 (en) Therapeutic agents
GB9711114D0 (en) Therapeutic agents
GB9700939D0 (en) Therapy
GB9816556D0 (en) Therapy
GB9702392D0 (en) Therapeutic agents
GB9700555D0 (en) Therapeutic agents
GB9723999D0 (en) Therapeutic use
GB9726701D0 (en) Therapeutic use
GB9726702D0 (en) Therapeutic use
GB9806039D0 (en) Therapy
GB9704885D0 (en) Therapy
GB9605525D0 (en) Therapy
GB9605466D0 (en) Therapy
GB9721173D0 (en) Therapeutic use
GB9717260D0 (en) Therapeutic use
GB9721265D0 (en) Therapeutic use